1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDA Grant Funding Opportunity Participation is sponsored by National Institute on Drug Abuse (NIDA). NIDA offers various funding opportunities for research related to drug use and addiction, aiming to advance science and improve individual and public health.
This includes research on identifying emerging drugs, improving data timeliness, understanding overdose mortality drivers, examining factors influencing risk/resilience for substance use, developing prevention interventions, understanding mechanisms of SUD, recovery, and relapse, identifying new intervention targets, advancing research on neuroplasticity, addressing disparities, developing treatment and recovery interventions, and advancing the training of scientists.
Get alerted about grants like this
Save a search for “National Institute on Drug Abuse (NIDA)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
As of October 2025, the NIDA Funding App has been retired. The NIH announcement stating this change can be read here: NOT-OD-25-143 . NIDA Funding Strategy – A review of NIDA’s strategy for funding, based on programmatic priorities.
Notice of Special Interest (NOSI) - Formerly known as Drug Abuse Topics of Special/Continuing Interest (DAT) NIDA Challenges Program – Crowd-sourced opportunities for providing solutions for particular goals. Helping to End Addiction Long-term (HEAL) Initiative – Congressional initiative to address the opioid overdose crisis. NIDA International Program – International research collaboration opportunities on drug abuse and addiction.
See NIDA’s Resources for Grants & Contracts to learn more about applying for a grant and the pre-approval and approval process. Administrative Supplements for Grants & Cooperative Agreements Administrative Supplements for Grants & Cooperative Agreements – Additional funding to an active NIDA grant or cooperative agreement.
Supplemental Information for NOFOs Supplemental Information for NOT-DA-22-064: Notice of Intent to Publish a Funding Opportunity Announcement for NIH Brain Development Cohorts Biospecimen Access FAQs for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders - RFA-DA-24-007.
FAQs for Registry of Medical Cannabis Use and Health Outcomes: RFA-DA-23-011 Supplemental Information for NIH Developmental Studies Biospecimen Access Program FAQs for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders - RFA-DA-23-014 Pre-Application Information Webinar for PAR-21-183, "Developing Digital Therapeutics for Substance Use Disorders FAQs Regarding Notice of Information: Establishment of a Standard THC Unit to be Used in Research (NOT-DA-21-049) Frequently Asked Questions about NOT-DA-21-041: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus RFA-DA-21-009: Pre-Application Webinar and FAQs- Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research - RFA-DA-20-025 FAQs for Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) FAQs for NOT-DA-19-003: HEAL Initiative: Request for Administrative Supplements to Existing Grants to Accelerate Research on Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) Supplemental Information (FAQs) for NIDA Research E-cigarette - PAR-17-156 Supplemental Information (FAQs) for RFA-DA-17-014 and RFA-DA-17-023
Based on current listing details, eligibility includes: NIDA supports a multidisciplinary new generation of scientists and a range of research institutions. Eligibility varies by specific funding opportunity, but generally includes public and private institutions, and individuals. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies by opportunity Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This NOFO supports small business concerns (SBCs) to develop technologies for commercialization that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. The goal is to improve outcomes for individuals struggling with SUD by mitigating the influence of social determinants of health and health-related social needs.
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA). Supports research projects at the intersection of HIV and substance use, aiming to open new areas of HIV/AIDS research and lead to new avenues for prevention, treatment, and cure of HIV among people who use addictive substances.
NIDA Cutting-Edge Basic Research Awards (CEBRA) is a grant from the National Institute on Drug Abuse (NIDA) that funds high-risk, high-impact basic research in substance use disorders (SUDs) that falls outside current research portfolios. Delivered through the R21 Exploratory/Developmental Research Grant mechanism, CEBRA supports up to $275,000 in direct costs over two years. Projects must be genuinely novel and not incremental extensions of ongoing work; alcohol-only studies are not eligible. Both established SUD researchers and investigators from other disciplines bringing fresh approaches are welcome to apply. Any domestic or foreign institution eligible for NIH funding may submit, with a next deadline of August 2026.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.